¼¼°èÀÇ ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀå
Non-opioid Pain Treatment
»óǰÄÚµå : 1775034
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀåÀº 2030³â±îÁö 660¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 440¾ï ´Þ·¯·Î ÃßÁ¤µÈ ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 660¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦´Â CAGR 8.0%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 296¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ ÀǾàǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 120¾ï ´Þ·¯, Áß±¹Àº CAGR 11.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀåÀº 2024³â¿¡ 120¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 139¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 11.1%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.4%¿Í 6.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼¼°è ÇコÄÉ¾î »ê¾÷ÀÌ ¿ÀÇÇ¿ÀÀÌµå ±â¹Ý ÅëÁõ °ü¸®¿¡¼­ ¹þ¾î³ª°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦·ÎÀÇ ÀüȯÀº Çö´ë ÅëÁõ °ü¸®¿¡¼­ °¡Àå Áß¿äÇÑ º¯È­ Áß ÇϳªÀ̸ç, ¿ÀÇÇ¿ÀÀ̵å Áßµ¶°ú ÀÇÁ¸¼º, °ü·Ã ÀÇ·áºñ ºÎ´ã¿¡ ´ëÇÑ ¿ì·Á Áõ°¡·Î ÀÎÇØ Ã˹ߵǾú½À´Ï´Ù. ƯÈ÷ ºÏ¹Ì¿¡¼­´Â ¼ö½Ê³âµ¿¾È ¿ÀÇÇ¿ÀÀÌµå ¿À³²¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»óÀÇ, ±ÔÁ¦ ´ç±¹, Á¦¾àȸ»ç Çõ½Å°¡µéÀÌ ±Þ¼º ¹× ¸¸¼º ÅëÁõ¿¡ ´ëÇØ º¸´Ù ¾ÈÀüÇϰí ÀÇÁ¸¼ºÀÌ ¾ø´Â ´ëü ¾à¹°À» ¿ì¼±ÀûÀ¸·Î »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ¿ÀÇÇ¿ÀÀÌµå °ú´Ù ó¹æÀÌ ÃÊ·¡ÇÑ Ä¡¸íÀûÀÎ °á°ú´Â ±ÔÁ¦ ´ç±¹ÀÇ ´Ü¼Ó, ÀÇ·á Áöħ °³Á¤, ÅëÁõ Ä¡·á ¹æ¹ý¿¡ ´ëÇÑ ¹®È­Àû Àç°ËÅä·Î À̾îÁ³½À´Ï´Ù. ±× °á°ú, ºñ¿ÀÇÇ¿ÀÀ̵å Ä¡·á(ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦, Ç׿ì¿ïÁ¦, Ç×°æ·ÃÁ¦ µî), Ç¥Àû »ý¹°ÇÐÀû Á¦Á¦, ½Å°æÂ÷´ÜÁ¦, TENS(°æÇÇÀû Àü±â½Å°æÀÚ±Ø) ¹× ô¼öÀڱرâ¿Í °°Àº ±â±¸¸¦ ÀÌ¿ëÇÑ Ä¡·á µî ´Ù¾çÇÑ Ä¡·á°¡ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·áÀÇ ´ëºÎºÐÀº ±âºÐÀ̳ª ÀÎÁö±â´ÉÀ» º¯È­½ÃŰ°Å³ª ÀÇÁ¸ÀÇ À§Çè ¾øÀÌ ÅëÁõÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö Àֱ⠶§¹®¿¡ °üÀý¿°À» ¾Î°í ÀÖ´Â °í·ÉÀÇ È¯ÀÚºÎÅÍ ½ºÆ÷Ã÷ ¿Ü»óÀ̳ª ¼ö¼ú ÈÄ È¸º¹ ÁßÀÎ ÀþÀº Ãþ±îÁö ¸ðµç ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. ¿ÏÈ­ Ä¡·á ¹× ¼ö¼ú ÈÄ Ä¡·á¿¡¼­ ºñ¿ÀÇÇ¿ÀÀÌµå ¿ä¹ýÀ» ¹°¸®Ä¡·á, ½É¸®Àû Áö¿ø, »ýȰ½À°ü Á¶Á¤°ú ÅëÇÕÇÏ´Â ¸ÖƼ¸ð´Þ Á¢±Ù¹ýÀÌ ÁÖ·ù°¡ µÇ°í ÀÖ½À´Ï´Ù. ¿ÀÇÇ¿ÀÀ̵åÀÇ À§Ç輺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚµéÀº ÀÇÇÐÀû °ü¸® ÇÏ¿¡ º¹¿ëÇÏ´õ¶óµµ ºñ¿ÀÇÇ¿ÀÀÌµå ´ë¾ÈÀ» ã°í ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÇ·á ½Ã½ºÅÛ¿¡´Â ´õ ¸¹Àº ÁøÈ­¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÆÐ·¯´ÙÀÓÀÇ º¯È­·Î ÀÎÇØ ÅëÁõ Ä¡·á´Â ´Ü¼øÇÑ ÀÓ»óÀû °úÁ¦°¡ ¾Æ´Ñ, ´ÙÇÐÁ¦ÀûÀÌ°í °³º°È­µÈ °øÁߺ¸°Ç Áß½ÉÀÇ ¿ì¼±¼øÀ§·Î ÀçÁ¤Àǵǰí ÀÖ½À´Ï´Ù.

¾à¸®ÇÐ ¹× ÀÇ·á±â±âÀÇ Çõ½ÅÀº ÅëÁõ Ä¡·áÀÇ µµ±¸ »óÀÚ¸¦ ¾î¶»°Ô È®ÀåÇϰí Àִ°¡?

ÃÖ±Ù ¾à¸®ÇÐ ¹× ÀÇ·á ±â¼ú ºÐ¾ßÀÇ Çõ½ÅÀº ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅë Ä¡·áÀÇ ¹üÀ§¿Í È¿´ÉÀ» Å©°Ô È®´ëÇÏ¿© ¸¶¾à¿¡ ÀÇÁ¸ÇÏ´ø ¼ö¹é¸¸ ¸íÀÇ È¯Àڵ鿡°Ô Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. Á¦¾à¾÷°è´Â ³úÀÇ º¸»ó ü°è¿¡ ¿µÇâÀ» ÁÖÁö ¾Ê°í ƯÁ¤ ÅëÁõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï´Â »õ·Î¿î È­ÇÕ¹°À» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼±ÅÃÀû ½Å°æ¼ºÀåÀÎÀÚ(NGF) ¾ïÁ¦Á¦´Â °ñ°üÀý¿°°ú °°Àº ¸¸¼ºÁúȯ¿¡ À¯¸ÁÇϸç, COX-2 ¾ïÁ¦Á¦ ¹× Â÷¼¼´ë ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦´Â À§Àå À§ÇèÀ» ÁÙÀ̸鼭 ÁøÅë È¿°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. °æ±¸¿ë ¾à¹°»Ó¸¸ ¾Æ´Ï¶ó ±¹¼Ò¿ë Á©, °æÇÇ ÆÐÄ¡, ÁÖ»ç °¡´ÉÇÑ »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº ±¹¼Ò Àü´Þ ½Ã½ºÅÛÀº Àü½Å ³ëÃâÀ» ÃÖ¼ÒÈ­Çϸ鼭 ºÎÀ§º° ¿ÏÈ­¸¦ Á¦°øÇÕ´Ï´Ù. ÀÇ·á±â±â Ãø¸é¿¡¼­´Â TENS ÀåÄ¡³ª ½Å°æ Á¶Àý ÀÓÇöõÆ®¿Í °°Àº ½Å°æ ½ÅÈ£¸¦ Á¶ÀýÇÏ´Â ¿þ¾î·¯ºí ±â¼úÀÌ ½Å°æÀå¾Ö, ¼¶À¯±ÙÀ°Åë, ¼ö¼ú ÈÄ ÅëÁõ°ú °°Àº Áõ»ó¿¡ ´ëÇÑ È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñħ½ÀÀû ¶Ç´Â Àúħ½ÀÀû ÀåÄ¡´Â ȯÀÚ°¡ ¾à¸®ÇÐÀû °³ÀÔ ¾øÀÌ Àå±âÀûÀÎ Áõ»ó °ü¸®¸¦ ÇÊ¿ä·Î ÇÏ´Â ¿Ü·¡ ȯÀڵ鿡°Ô ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù. ¶ÇÇÑ, °¡»óÇö½Ç(VR) ±â¹Ý Ä¡·á¹ýµµ ÀÓ»ó½ÃÇè¿¡¼­ ÅëÁõ ¿ÏÈ­¸¦ À§ÇØ »ê¸¸ÇÔÀ̳ª ÀÎÁöÀû À籸¼º ±â¼úÀ» ÀÌ¿ëÇÑ Ä¡·á¹ýµµ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, AI ±â¹Ý Ç÷§ÆûÀº À¯ÀüÇÐ, Çൿ, ¶óÀÌÇÁ½ºÅ¸ÀÏ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ÀÓ»óÀǰ¡ ȯÀÚ °³°³Àο¡ ¸Â°Ô ÅëÁõ Ä¡·á ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ, µðÁöÅÐ Ä¡·áÇÐ, Á¤¹ÐÀÇ·áÀÇ À¶ÇÕÀº ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦¸¦ ½ÇÇöÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¸¹Àº °æ¿ì ¹Ù¶÷Á÷ÇÑ Ä¡·á¹ýÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÅëÁõ¿¡ ´ëÇÑ ÀÌÇØ¿Í ´ëó ¹æ½ÄÀ» º¯È­½Ã۰í ÀÖÀ¸¸ç, ÅëÁõ ¾ïÁ¦¿¡¼­ Á¶Àý°ú Àå±âÀû °ü¸®·Î ÃÊÁ¡À» ¿Å±â°í ÀÖ½À´Ï´Ù.

°øÁߺ¸°Ç Á¤Ã¥°ú ÁöºÒÀÚ Àü·«ÀÌ ºñ¿ÀÇÇ¿ÀÀÌµå ´ë¾ÈÀ¸·ÎÀÇ ÀüȯÀ» °¡¼ÓÈ­Çϰí Àִ°¡?

ºñ¿ÀÇÇ¿ÀÀ̵å ÅëÁõ Ä¡·áÀÇ º¸±ÞÀº ¿ÀÇÇ¿ÀÀ̵å ÀÇÁ¸¼º ¾ïÁ¦¸¦ À§ÇÑ °øÁߺ¸°Ç Á¤Ã¥, º¸Çè ÁöºÒÀÚ Àü·«, ÀÇ·á±â°üÀÇ Ã³¹æ °¡À̵å¶óÀο¡ ÀÇÇØ Å©°Ô ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±¹°¡Àû ¿ÀÇÇ¿ÀÀ̵å À§±â ÀÌÈÄ ¹Ì±¹, ij³ª´Ù, È£ÁÖ¸¦ ºñ·ÔÇÑ ¼¼°è °¢±¹ Á¤ºÎ´Â ¾ö°ÝÇÑ Ã³¹æ °¨½Ã ÇÁ·Î±×·¥À» ½ÃÇàÇÏ°í ºñ¿ÀÇÇ¿ÀÀÌµå °è¿­ ÅëÁõ Ä¡·áÁ¦ÀÇ °³¹ß ¹× º¸±ÞÀ» À§ÇÑ º¸Á¶±ÝÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, FDA¿Í °°Àº ±ÔÁ¦ ±â°üÀº ´ëü ¾à¹°ÀÇ ±ä±ÞÇÑ Çʿ伺À» ÀνÄÇϰí ÀϺΠºñ¿ÀÇÇ¿ÀÀÌµå °è¿­ ÁøÅëÁ¦ÀÇ ºñ ¿ÀÇÇ¿ÀÀÌµå °è¿­ ÁøÅëÁ¦ ¹× ±â±¸ÀÇ ½ÂÀÎÀ» ¼­µÎ¸£°í ÀÖ½À´Ï´Ù. º¸Çè»çµéÀº ¹°¸®Ä¡·á, ħ¼ú, Ä«ÀÌ·ÎÇÁ·¢Æ½, ÀÎÁöÇൿġ·á(CBT)¿Í °°Àº ºñ¾à¹° ¿ä¹ýÀ» Æ÷ÇÔÇÑ ºñ¿ÀÇÇ¿ÀÀÌµå ¿ä¹ýÀ» º¸´Ù ±¤¹üÀ§ÇÏ°Ô Àû¿ëÇϱâ À§ÇØ º¸Çè±Ý Áö±Þ ü°è¸¦ °³Á¤Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϺΠÀÇ·á ½Ã½ºÅÛ¿¡¼­´Â ¿ÀÇÇ¿ÀÀÌµå º¸Á¸ ÇÁ·ÎÅäÄÝÀ» äÅÃÇÏ´Â º´¿ø ¹× Ŭ¸®´Ð¿¡ ÀçÁ¤Àû Àμ¾Æ¼ºê¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, Á¤Çü¿Ü°ú, Ä¡°ú, ¸¶Ãë°ú, ¿ÏÈ­Ä¡·á µî °¢ Àü¹®°¡ ´Üü´Â ƯÁ¤ Áúȯ ¹× ¼ö¼ú ÈÄ ½Ã³ª¸®¿À¿¡ ´ëÇÑ 1Â÷ ¼±Åà ġ·á·Î ¿ÀÇÇ¿ÀÀ̵带 »ç¿ëÇÏÁö ¾Ê´Â ´ë¾ÈÀ» ±ÇÀåÇÏ´Â Ãֽа¡À̵å¶óÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù. ¿ÀÇÇ¿ÀÀ̵åÀÇ Àå±âÀûÀÎ À§Ç輺À» °­Á¶ÇÏ°í º¸´Ù ¾ÈÀüÇÏ°í ±Ù°Å¿¡ ±â¹ÝÇÑ ´ë¾ÈÀ» Á¦½ÃÇÏ´Â ±³À° Ä·ÆäÀÎÀÌ ÀÇ»ç¿Í ÀϹÝÀÎ ¸ðµÎ¸¦ ´ë»óÀ¸·Î µ¿½Ã¿¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. º´¿ø°ú ´ëÇк´¿ø¿¡¼­´Â ¿©·¯ ºñ¿ÀÇÇ¿ÀÀÌµå ¿ä¹ýÀ» ÅëÇÕÇÏ¿© Á¾ÇÕÀûÀ¸·Î ÅëÁõÀ» Ä¡·áÇÏ´Â Àü¿ë ÅëÁõ °ü¸® ÇÁ·Î±×·¥À» ½ÃÀÛÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥Àû Â÷¿øÀÇ ³ë·ÂÀº ÀÇ·á ÇàÀ§ ±âÁØÀ» À籸¼ºÇÒ »Ó¸¸ ¾Æ´Ï¶ó ºñ¾à¹° ¹× ºñ¿ÀÇÇ¿ÀÀ̵å Á¢±Ù¹ý¿¡ ´ëÇÑ Æí°ßÀ» ÁÙÀ̰í Áö¼Ó °¡´ÉÇϰí ȯÀÚ Áß½ÉÀÇ »õ·Î¿î ÅëÁõ °ü¸® ¹®È­¸¦ Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.

¼¼°è ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú, ÀÇ·á ¼­ºñ½º Á¦°ø, ȯÀÚ Çൿ, ¿ªÇÐ µ¿Çâ µî ¿©·¯ °¡Áö ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀûÀ¸·Î´Â »ý¹°ÇÐÀû Á¦Á¦, ½Å°æÂ÷´ÜÁ¦, µðÁöÅÐ Ä¡·áÁ¦ µî º¸´Ù ¾ÈÀüÇϰí Ç¥ÀûÈ­µÈ Ä¡·á¹ýÀÇ °³¹ß·Î ÀÎÇØ ºñ¿ÀÇÇ¿ÀÀ̵å ÅëÁõ °ü¸®ÀÇ ÀÓ»óÀû ÀáÀç·ÂÀÌ º¸´Ù ±¤¹üÀ§ÇÑ º´Å»ý¸®¿¡¼­ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­, ÁÂ½Ä »ýȰ, ¼ö¼ú, °üÀý¿°, ¾Ï, ´ç´¢º´ µîÀÇ Áúº´À¸·Î ÀÎÇÑ ¸¸¼º ÅëÁõÀÇ À¯º´·ü Áõ°¡´Â È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ ÁÁÀº ÅëÁõ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä¸¦ Áö¼ÓÀûÀ¸·Î âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÓ»óÀû Ãø¸é¿¡¼­´Â ´ÙÇÐÁ¦Àû Ä¡·áÆÀ°ú °³º°È­µÈ ÀÇ·á Á¢±Ù¹ýÀÇ ÅëÇÕÀÌ ´Ù¾çÇϰí Áßµ¶¼ºÀÌ ¾ø´Â Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½Ã½ºÅÛ Ãø¸é¿¡¼­ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ¹ýÀû Ã¥ÀÓÀ» ÁÙÀ̰í, ȯÀÚ ¸¸Á·µµ¸¦ ³ôÀ̰í, ±â°üÀÇ ¼º°ú ÁöÇ¥¸¦ ÃæÁ·Çϱâ À§ÇØ ¿ÀÇÇ¿ÀÀÌµå º¸Á¸ Àü·«À» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù. º¸Çè Àû¿ëÀº Á¡Â÷ ºñ¿ÀÇÇ¿ÀÀÌµå ¿ä¹ý¿¡ ´ëÇÑ º¸Çè Àû¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚµéÀÇ Á¢±Ù¼ºÀ» ³ôÀÌ°í º»ÀÎ ºÎ´ã±ÝÀ» ³·Ãß°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Ãø¸é¿¡¼­´Â °Ç°­ ¹®ÇØ·ÂÀÌ Çâ»óµÇ°í ¿ÀÇÇ¿ÀÀÌµå °ü·Ã ¾à¹° ÇÇÇØ¿¡ ´ëÇÑ »çȸÀû ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚµéÀÌ Àû±ØÀûÀ¸·Î ´ëü Ä¡·á¹ýÀ» ã°í ´õ ¾ÈÀüÇÑ Ä¡·á °æ·Î¸¦ ÁöÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹ÍÀº ¿ÀÇÇ¿ÀÀ̵å ÀÇÁ¸¼º ½Ã½ºÅÛÀÇ Ãë¾à¼ºÀ» µå·¯³»¸é¼­ Áý¿¡¼­ °ü¸®ÇÒ ¼ö ÀÖ´Â ºÐ»êÇü, ±â±â ±â¹Ý ¶Ç´Â ºñ¾à¹°Àû °³ÀÔÀÇ Á߿伺À» ´õ¿í ÀÔÁõÇß½À´Ï´Ù. Á¦¾à ¹× ÀÇ·á ±â¼ú ±â¾÷µéÀº źźÇÑ R&D ÆÄÀÌÇÁ¶óÀΰú ¼¼°è ½ÃÀå ħÅõ¸¦ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû, ÀÓ»óÀû, °æÁ¦Àû, ¹®È­Àû º¯È­·Î ÀÎÇØ ºñ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦ ½ÃÀåÀº Áö¼ÓÀûÀÌ°í °¡¼ÓÈ­µÈ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ºÎ¹®

¾àÁ¦ Ŭ·¡½º(ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦, ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ¾à, ±¹¼Ò ¸¶ÃëÁ¦, ±âŸ ¾àÁ¦ Ŭ·¡½ºº°);ÅëÁõ(¸¸¼º ÅëÁõ, ¼ö¼úÈÄ ÅëÁõ, ¾Ï¼º ÅëÁõ, ±âŸ ÅëÁõ);Åõ¿© °æ·Î(°æ±¸Åõ¿© °æ·Î, ±¹¼Ò Åõ¿© °æ·Î, ÁÖ»ç Åõ¿© °æ·Î, ±âŸ Åõ¿© °æ·Î);À¯Åë ä³Î(¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Äõ¸® ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Non-opioid Pain Treatment Market to Reach US$66.0 Billion by 2030

The global market for Non-opioid Pain Treatment estimated at US$44.0 Billion in the year 2024, is expected to reach US$66.0 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Non-Steroidal Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$29.6 Billion by the end of the analysis period. Growth in the Acetaminophen Drugs segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.0 Billion While China is Forecast to Grow at 11.1% CAGR

The Non-opioid Pain Treatment market in the U.S. is estimated at US$12.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.9 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Non-Opioid Pain Treatment Market - Key Trends & Drivers Summarized

Why Is the Global Healthcare Industry Moving Away from Opioid-Based Pain Management?

The global transition toward non-opioid pain treatment represents one of the most significant shifts in modern pain management, catalyzed by growing concerns over opioid addiction, dependence, and associated healthcare burdens. In response to decades of rising opioid misuse-particularly in North America-clinicians, regulators, and pharmaceutical innovators are prioritizing safer, non-addictive alternatives for both acute and chronic pain. The devastating consequences of opioid overprescription have led to regulatory crackdowns, medical guideline revisions, and a major cultural rethinking of how pain should be treated. This has created a fertile environment for non-opioid treatments, which include a wide range of pharmaceuticals (such as NSAIDs, antidepressants, and anticonvulsants), targeted biologics, nerve-blocking agents, and device-based therapies like TENS (Transcutaneous Electrical Nerve Stimulation) and spinal cord stimulators. Many of these treatments can effectively manage pain without altering mood, cognitive function, or risking dependence, making them attractive across patient demographics-from elderly patients with arthritis to younger populations recovering from sports injuries or surgeries. In palliative and post-operative care, multimodal approaches are now becoming the norm, wherein non-opioid solutions are integrated with physical therapy, psychological support, and lifestyle adjustments. As awareness grows around the risks of opioids-even when taken under medical supervision-patients themselves are increasingly seeking out and requesting non-opioid alternatives, placing additional pressure on healthcare systems to evolve. This global paradigm shift is redefining pain treatment not just as a clinical challenge but as a multidisciplinary, personalized, and public health-driven priority.

How Are Innovations in Pharmacology and Medical Devices Expanding the Pain Treatment Toolbox?

Recent innovations in pharmacology and medical technology are vastly expanding the range and efficacy of non-opioid pain treatments, offering hope for millions of patients previously dependent on narcotics for relief. On the pharmaceutical front, companies are developing novel compounds that target specific pain pathways without affecting the brain’s reward system-thereby reducing the potential for misuse. For instance, selective nerve growth factor (NGF) inhibitors are showing promise for chronic conditions like osteoarthritis, while COX-2 inhibitors and next-generation NSAIDs are delivering improved pain relief with reduced gastrointestinal risks. Beyond oral drugs, localized delivery systems such as topical gels, transdermal patches, and injectable biologics offer site-specific relief with minimal systemic exposure. On the medical device side, wearable technologies that modulate nerve signals-like TENS units and neuromodulation implants-are emerging as effective solutions for conditions such as neuropathy, fibromyalgia, and post-surgical pain. These non-invasive or minimally invasive devices are particularly appealing in outpatient settings where patients require long-term symptom management without pharmacologic intervention. Virtual reality (VR)-based therapies, which use distraction and cognitive reframing techniques, are also being explored for pain reduction in clinical trials. Meanwhile, AI-powered platforms are helping clinicians tailor pain treatment regimens to individual patients by analyzing genetics, behavior, and lifestyle data. The convergence of biotechnology, digital therapeutics, and precision medicine is making non-opioid pain treatment not only viable but in many cases, preferable. These innovations are transforming how pain is understood and addressed-shifting the focus from suppression to modulation and long-term management.

Are Public Health Policies and Payer Strategies Accelerating the Shift to Non-Opioid Options?

The rising adoption of non-opioid pain treatments is being significantly driven by public health policies, insurance payer strategies, and institutional prescribing guidelines aimed at curbing opioid dependency. In the wake of national opioid crises, governments across the globe-especially in the U.S., Canada, and Australia-are implementing stringent prescription monitoring programs and providing grants for the development and dissemination of non-opioid pain solutions. Regulatory agencies like the FDA have fast-tracked approval for several non-opioid pain relief drugs and devices, recognizing the urgent need for alternatives. Insurance companies are revising reimbursement frameworks to support broader coverage of non-opioid therapies, including non-pharmacological interventions such as physical therapy, acupuncture, chiropractic care, and cognitive behavioral therapy (CBT). Some healthcare systems are also introducing financial incentives for hospitals and clinics that adopt opioid-sparing protocols. Moreover, professional associations in orthopedics, dentistry, anesthesiology, and palliative care have issued updated guidelines recommending non-opioid options as first-line treatments for specific conditions or post-operative scenarios. Educational campaigns are simultaneously targeting both physicians and the public, emphasizing the long-term dangers of opioids and presenting safer, evidence-based alternatives. Hospitals and academic medical centers are launching dedicated pain management programs that integrate multiple non-opioid modalities to treat pain holistically. These policy-level efforts are not only reshaping medical practice standards but are also reducing stigma around non-drug and non-opioid approaches, fostering a new culture of sustainable, patient-centered pain management.

What Factors Are Driving the Growth of the Non-Opioid Pain Treatment Market Globally?

The growth in the non-opioid pain treatment market is driven by several interlinked factors spanning technology, healthcare delivery, patient behavior, and epidemiological trends. Technologically, the development of safer, more targeted therapies-including biologics, nerve blockers, and digital therapeutics-is expanding the clinical viability of non-opioid pain management across a wider array of conditions. The increasing prevalence of chronic pain-stemming from aging populations, sedentary lifestyles, surgical procedures, and conditions like arthritis, cancer, and diabetes-is creating sustained global demand for effective and tolerable pain solutions. Clinically, the integration of multidisciplinary care teams and personalized medicine approaches is reinforcing the need for diverse, non-addictive treatment modalities. From a systems perspective, healthcare providers are prioritizing opioid-sparing strategies to reduce legal liabilities, improve patient satisfaction, and meet institutional performance metrics. Insurance coverage is gradually becoming more inclusive of non-opioid therapies, enabling broader patient access and reducing out-of-pocket costs. On the consumer side, growing health literacy and social awareness around opioid-related harm are pushing patients to actively seek alternative treatments and advocate for safer care pathways. Additionally, the COVID-19 pandemic exposed the vulnerability of opioid-dependent systems, further validating the importance of decentralized, device-based, or non-pharmacologic interventions that can be managed at home. Pharmaceutical companies and medtech firms are responding with robust R&D pipelines and strategic partnerships aimed at expanding market penetration globally. Together, these technological, clinical, economic, and cultural shifts are driving a durable and accelerating wave of growth in the non-opioid pain treatment market.

SCOPE OF STUDY:

The report analyzes the Non-opioid Pain Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Non-Steroidal Anti-Inflammatory Drugs, Acetaminophen Drugs, Local Anesthetics Drugs, Other Drug Classes); Pain (Chronic Pain, Post-operative Pain, Cancer Pain, Other Pains); Route of Administration (Oral Route of Administration, Topical Route of Administration, Injectable Route of Administration, Other Route of Administrations); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â